CurrentCentenePolicy CP PHAR.676

Aprocitentan (Tryvio) for hypertension

Defines medical necessity criteria, prior authorization requirements, dosing limits, contraindications, and coverage duration for Tryvio (aprocitentan) to treat hypertension across Commercial, HIM, and Medicaid lines of business affiliated with Centene Corporation.

Policy Summary

PayerCentene

PolicyAprocitentan (Tryvio) for hypertension

Policy CodePolicy CP PHAR.676

Change TypeAnnual review (no significant changes)

Effective DateJun 1, 2024

Next Review Date

Key ActionProvider must submit office chart notes, lab results or other clinical information supporting diagnosis of hypertension, recent BP within 30 days demonstrating ≥140/90 mmHg, adherence for ≥4 weeks to at least three antihypertensive classes at maximally tolerated doses, and current medication regimen showing ≥3 classes; include rationale if fewer than 3 classes due to contraindication or adverse effects.

SourceLink

POLICY UPDATE CHANGES

2Q 2025 annual review: no significant changes; references reviewed and updated.

Policy created and P&T approved in 05.24

1Covered indication (hypertension)

12.5 mgMaximum daily dose (tablet strength)

6 monthsInitial approval duration

3+Required concomitant antihypertensive drug classes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.